Temporal variations of thermospheric hydrogen derived from in situ measurements

Diurnal variations of atomic hydrogen in thermosphere derived from Explorer 32 data and correlated with solar cycle, solar rotation, and earth rotatio

Thermospheric hydrogen - Absolute densities and temporal variations deduced from in situ measurements

Thermospheric model based on Explorer 32 hydrogen ion density measurements including periodic variations and temperature factors due to local time, solar activity, and magnetic effect

In situ measurements of plasma drift velocity and enhanced NO(+) in the auroral electroject by the Bennett spectrometer on AE-C

Simultaneous measurements of ion composition and plasma drift velocity by the Bennett mass spectrometer on the Atmosphere Explorer-C satellite reveal a direct correlation between enhancements in NO(+) concentration and ion drift velocity in the southern auroral oval. Low altitude (137 to 250 km) nighttime data reveal a region of westward plasma flow at velocities up to 1.3 km/s between 62 deg and 68 deg invariant latitude, with corresponding NO(+) enhancements of up to a factor of 25. A narrow region of reverse flow at approximately 0.9 km/s was also measured. These drift observations are consistent with convective flow patterns derived from electric field measurements, and their correlation with NO(+) appears to support the suggestion that NO(+) enhancements would be expected in regions of drift owing to the dependence on ion energy of the reaction O(+) + N2 yields NO(+) + N

Altitude variation of ion composition in the midlatitude trough region - Evidence for upward plasma flow

Altitude effect on ion concentration in midlatitude trough and plasmaspher

Direct measurements of helium and hydrogen ion concentration and total ion density to an altitude of 940 kilometers

Measurement of ion concentration and total ion density in exosphere using mass spectrometer and electrostatic prob

A Rare Case Of Metastatic Insulinoma In A Patient With Huntington’s Disease

A Rare Case Of Metastatic Insulinoma In A Patient With Huntington’s Disease Olesya Petrenko, DO Providence Portland Medical Center – Portland, OR Additional Authors: Brinton Clark, MD, FACP A 49-year-old female with past medical history of Huntington’s disease presents to the ED after being found unresponsive at her assisted-living facility. She was noted to be hypoglycemic with a glucose of 21 and responded to dextrose. For the past several months, patient had symptoms of dizziness, tremors. She has no history of diabetes, and only home medication is Zyprexa. Patient required D10 drip to maintain glucose levels. Given patient’s psychiatric history, there was concern for surreptitious use of diabetic medications. Labwork showed an insulin level of 163 and an elevated C-peptide of 7.0 consistent with endogenous insulin secretion. Patient underwent a 72-hour fasting protocol which revealed a glucose of 23, C-peptide of 4.1 and insulin of 101, undetectable beta-hydroxybutyrate levels and pro-insulin level of 782 (normal \u3c8), which are consistent with a diagnosis of insulinoma. She was started on diazoxide, which diminishes insulin secretion, to treat the hypoglycemia. Patient underwent a pancreas CT protocol which showed multiple hypervascular hepatic masses up to 9 cm and one 4 cm mass in pancreatic tail concerning for metastasis. Pathology revealed metastatic well-differentiated neuroendocrine tumor grade 3. She was not a candidate for surgical resection of tumors and she was started on Octreotide 200 mcg TID. Patient underwent two Y90 therasphere radioembolization treatments, 2 months apart with improvement of hypoglycemia and discontinuation of diazoxide. Patient remains on Octreotide LAR injection every 4 weeks with frequent glucose monitoring. Insulinoma, although rare, occurs in 1-4% of the population and is the most common type of functional neuroendocrine tumor of the pancreas. It secretes insulin which results in hyperinsulinemic hypoglycemia. Diagnosis involves persistent hypoglycemia with glucose \u3c50 mg/dL, neuroglycopenic symptoms and prompt relief after glucose administration. Gold standard diagnosis is a 72-hour fast and measurement of plasma insulin, C-peptide and pro-insulin, which detects 99% of insulinomas. After lab confirmation, imaging is necessary to localize the tumor with either CT, MRI or EUS. Surgical resection is curative in most patients. Other treatment modalities include injection of octreotide, EUS-aided alcohol ablation, radio-frequency ablation or embolization of insulinoma, as well as targeted therapy with everolimus or sunitinib. Malignant insulinomas are extremely rare and often invade into surrounding soft tissue or have lymph node or liver metastasis. They are usually unresectable and require targeted therapy. We present the case of a 49-YO patient with Huntington’s disease who presented with severe persistent hypoglycemia secondary to metastatic insulinoma. Diagnosis of insulinoma is often delayed or missed as symptoms may be attributed to psychiatric, cardiac or neurological disorders or medication misuse. Clinicians should be aware of insulinoma as a cause of life-threatening hypoglycemia.https://digitalcommons.psjhealth.org/ppmc_internal/1012/thumbnail.jp

Observation of hydrogen and helium ions during a period of rising solar activity

Latitudinal variations in H and He ion distribution in upper ionosphere observed by OGO 2 and 4 satellites during rising solar activit